BioLineRx Ltd. (NASDAQ:BLRX) – Equities researchers at Roth Capital lowered their FY2016 earnings per share (EPS) estimates for shares of BioLineRx in a report issued on Tuesday. Roth Capital analyst J. Pantginis now expects that the firm will post earnings per share of ($0.28) for the year, down from their previous forecast of ($0.27). Roth Capital has a “Buy” rating and a $7.00 price objective on the stock. Roth Capital also issued estimates for BioLineRx’s FY2017 earnings at ($0.32) EPS.

Several other research analysts also recently weighed in on BLRX. Zacks Investment Research downgraded shares of BioLineRx from a “hold” rating to a “sell” rating in a research report on Thursday. Maxim Group set a $1.00 target price on shares of BioLineRx and gave the stock a “hold” rating in a research report on Tuesday. Finally, S&P Equity Research dropped their target price on shares of BioLineRx from $1.24 to $1.10 in a research report on Friday, September 23rd. One research analyst has rated the stock with a sell rating, one has issued a hold rating and three have assigned a buy rating to the stock. BioLineRx currently has a consensus rating of “Hold” and a consensus target price of $2.68.

Earnings History and Estimates for BioLineRx (NASDAQ:BLRX)

TRADEMARK VIOLATION NOTICE: This article was first published by The Cerbat Gem and is the sole property of of The Cerbat Gem. If you are accessing this article on another site, it was illegally stolen and republished in violation of U.S. and international copyright law. The correct version of this article can be accessed at https://www.thecerbatgem.com/2016/11/26/brokers-offer-predictions-for-biolinerx-ltd-s-fy2016-earnings-blrx.html.

Shares of BioLineRx (NASDAQ:BLRX) opened at 1.08 on Thursday. The stock has a 50 day moving average of $0.00 and a 200 day moving average of $0.00. BioLineRx has a 52-week low of $0.71 and a 52-week high of $1.63.

BioLineRx (NASDAQ:BLRX) last released its quarterly earnings data on Tuesday, November 22nd. The company reported ($0.08) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.07) by $0.01.

TRADEMARK VIOLATION NOTICE: This article was first published by The Cerbat Gem and is the sole property of of The Cerbat Gem. If you are accessing this article on another site, it was illegally stolen and republished in violation of U.S. and international copyright law. The correct version of this article can be accessed at https://www.thecerbatgem.com/2016/11/26/brokers-offer-predictions-for-biolinerx-ltd-s-fy2016-earnings-blrx.html.

Several hedge funds have recently bought and sold shares of BLRX. KCG Holdings Inc. boosted its stake in BioLineRx by 414.1% in the third quarter. KCG Holdings Inc. now owns 151,029 shares of the company’s stock valued at $174,000 after buying an additional 121,650 shares in the last quarter. Morgan Stanley boosted its stake in BioLineRx by 13.8% in the third quarter. Morgan Stanley now owns 551,122 shares of the company’s stock valued at $634,000 after buying an additional 66,900 shares in the last quarter. Finally, Senvest Management LLC boosted its stake in BioLineRx by 25.4% in the third quarter. Senvest Management LLC now owns 4,443,500 shares of the company’s stock valued at $5,110,000 after buying an additional 900,200 shares in the last quarter. Institutional investors and hedge funds own 14.35% of the company’s stock.

About BioLineRx

BioLine RX Ltd is an Israel-based company engaged in the development of therapeutics, from preclinical-stage development to advanced clinical trials, for a range of medical needs. Its clinical therapeutic candidates under development consist of BL-1020 that is in Phase II/III clinical trials to improve cognitive function in schizophrenia patients; BL-1040, which is under pivotal CE-Mark registration trial for the prevention of cardiac remodeling following an acute myocardial infarction; BL-5010, which has completed Phase I/II clinical trials for non-surgical removal of skin lesions; BL-1021 that has completed Phase Ia clinical trial for the treatment of neuropathic pain or pain that results from damage to nerve fibers, and BL-7040, a synthetic oligonucleotide, which is in Phase II clinical trial for the treatment of inflammatory bowel disease.

5 Day Chart for NASDAQ:BLRX

Receive News & Stock Ratings for BioLineRx Ltd. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for BioLineRx Ltd. and related stocks with our FREE daily email newsletter.